摘要
糖尿病肾病是糖尿病最常见的微血管并发症之一,也是糖尿病患者的重要死亡原因。糖尿病肾病早期临床症状不明显,尿微量白蛋白被广泛认为是糖尿病肾病的早期临床诊断标志物,但有许多患者在肾小球滤过率下降时并未出现蛋白尿,因此,将尿微量白蛋白作为糖尿病肾病早期诊断的敏感生物标志物存在局限性。本文对晚期糖基化终末产物、非对称性二甲基精氨酸、可溶性尿激酶型纤溶酶原激活物受体等新型生物标志物在糖尿病肾病早期诊断中的应用研究进展进行综述,以期为糖尿病肾病的早期诊断和治疗提供新的靶点。
Diabetic nephropathy is one of the most common microvascular complications of diabetes mellitus,it is also an important cause of death in diabetic patients.In the early stage of diabetic nephropathy,the clinical symptoms are not obvious.Urinary microalbumin has been widely regarded as an early clinical diagnostic marker of diabetic nephropathy,however,many patients didn't have proteinuria when the glomerular filtration rate decreased.Therefore urinary microalbumin as a sensitive biomarker for early detection for diabetic nephropathy is limited.This article reviews the research progress of appicication of some new biomarkers in early diagnosis of diabetic nephropathy,including advanced glycation end-products,asymmetric dimethylarginine,soluble urokinase-type plasminogen activator receptor,in order to provide new targets for early diagnosis and treatment of diabetic nephropathy.
作者
孙晨思
李海琦
刘波
SUN Chensi;LI Haiqi;LIU Bo(Department of Endocrinology,China-Japhan Union Hospital of Jilin University,Changchun 130031,Jilin Province,China;Department of Neurology,China-Japhan Union Hospital of Jilin University,Changchun 130031,Jilin Province,China)
出处
《新乡医学院学报》
CAS
2022年第2期197-200,共4页
Journal of Xinxiang Medical University
